2013 Fiscal Year Final Research Report
Development of new remedy for pulmonary fibrosis, focused on HB-EGF
| Project/Area Number |
23591171
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Fukuoka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UCHINO Junji 福岡大学, 医学部, 講師 (80432946)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TASHIRO Naoki 福岡大学, 医学部, 助教 (70613884)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 肺線維症 / HB-EGF |
|---|
| Research Abstract |
The aim of this study is to clarify the role of HB-EGF in respiratory diseases, especially pulmonary fibrosis and to develop new remedy for pulmonary fibrosis.
The expression of HB-EGF was elevated in the bleomycin induced pulmonary fibrosis in inflammation phase. Then the expression was decreased in fibrosis phase. The HB-EGF expression was down-regulated in clinical specimen from the idiopathic pulmonary fibrosis. Therefore, it was revealed that the expression of HB-EGF was down-regulated related to pulmonary fibrosis. We hypothesized that overexpression of HB-EGF might lead to rescue of pulmonary fibrosis. We administered of adenovirus vector of HB-EGF expression or recombinant HB-EGF into bleomycin induced pulmonary fibrosis model. However, the apparent attenuation was not attained. As a result, the expression of HB-EGF was down-regulated in pulmonary fibrosis, but overexpression of HB-EGF did not result in attenuation of pulmonary fibrosis in this study.
|
